1. Home
  2. KLRS vs NMI Comparison

KLRS vs NMI Comparison

Compare KLRS & NMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$4.94

Market Cap

116.8M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Municipal Income Fund Inc.

NMI

Nuveen Municipal Income Fund Inc.

HOLD

Current Price

$10.69

Market Cap

119.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLRS
NMI
Founded
2019
N/A
Country
United States
United States
Employees
20
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
116.8M
119.5M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
KLRS
NMI
Price
$4.94
$10.69
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
82.7K
31.4K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.14
$9.62
52 Week High
$11.88
$11.18

Technical Indicators

Market Signals
Indicator
KLRS
NMI
Relative Strength Index (RSI) 40.90 56.00
Support Level $4.35 $9.85
Resistance Level $5.38 $10.88
Average True Range (ATR) 0.37 0.27
MACD 0.06 0.02
Stochastic Oscillator 38.18 83.04

Price Performance

Historical Comparison
KLRS
NMI

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

About NMI Nuveen Municipal Income Fund Inc.

Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.

Share on Social Networks: